Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.62
-0.10 (-1.75%)
At close: Mar 3, 2026, 4:00 PM EST
5.61
-0.01 (-0.18%)
After-hours: Mar 3, 2026, 7:40 PM EST
Sagimet Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Sagimet Biosciences stock have an average target of 27, with a low estimate of 8.00 and a high estimate of 35. The average target predicts an increase of 380.43% from the current stock price of 5.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sagimet Biosciences stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 6 | 6 |
| Buy | 2 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +380.43% | Feb 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +416.01% | Feb 3, 2026 |
| Barclays | Barclays | Hold Initiates $8 | Hold | Initiates | $8 | +42.35% | Jan 28, 2026 |
| Citizens | Citizens | Buy Maintains $33 → $35 | Buy | Maintains | $33 → $35 | +522.78% | Nov 14, 2025 |
| Clear Street | Clear Street | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +416.01% | Oct 22, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
113.33K
EPS This Year
-1.72
from -1.45
EPS Next Year
-2.00
from -1.72
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 1.1M | ||||
| Avg | n/a | 113,332 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.60 | -1.68 | ||||
| Avg | -1.72 | -2.00 | ||||
| Low | -1.76 | -2.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.